|
|
Relationship between the expression of LncRNA PANDAR, miR-637 and clinicopathological parameters and prognosis of thyroid cancer |
AO Xueren LIAO Cong MA Kaimin SHEN Guoxi |
Department of Surgery, the Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510385, China
|
|
|
Abstract Objective To explore the expression levels of long non-coding RNA (LncRNA) PANDAR and microRNA-637 (miR-637) in thyroid cancer tissues, and to analyze their relationship with clinicopathological parameters and prognosis. Methods A total of 82 patients with thyroid cancer admitted to the Third Affiliated Hospital of Guangzhou University of Chinese Medicine from January 2015 to February 2017 were selected. The relative expression levels of LncRNA PANDAR and miR-637 in thyroid cancer tissues and adjacent tissues (more than 5 cm from the edge of the tumor tissues) were detected, while the relationship between the two indicators and the clinicopathological characteristics and prognosis of patients were analyzed. Results The relative expression of LncRNA PANDAR in thyroid cancer tissues was higher than that of adjacent tissues, and the relative expression of miR-637 was lower than that of adjacent tissues (P < 0.05). The expression of LncRNA PANDAR was negatively correlated with miR-637 (r = -0.634, P < 0.05). The expression of LncRNA PANDAR and miR-637 in thyroid cancer tissue were related to tumor TNM stage, cell differentiation degree, and lymphatic metastasis (P < 0.05). The 3-year overall survival rate of the LncRNA PANDAR high expression group was lower than that of the LncRNA PANDAR low expression group (P < 0.05). There was no significant difference in the 3-year overall survival rate between the miR-637 high expression group and the low expression group (P > 0.05). Conclusion The relative expression of LncRNA PANDAR in thyroid cancer tissues is higher than that in adjacent tissues, and the relative expression of miR-637 is lower than that in adjacent tissues. It is closely related to tumor TNM staging, cell differentiation and lymphatic metastasis. It is expected to become a new biological indicators in diagnosis, treatment and prognosis assessment of thyroid cance.
|
|
|
|
|
[1] 罗莎,唐万燕,李伟,等.甲状腺癌分子标志物研究进展[J].国际检验医学杂志,2020,41(9):1122-1126.
[2] 李洪利,俞魏,陈彤岩,等.甲状腺癌患者血清半乳糖凝集素-1、谷胱甘肽过氧化物酶3表达变化及其与疾病严重程度相关性研究[J].中华保健医学杂志,2020,22(2):191-193.
[3] 李云雪,王刚,孙备,等.甲状腺乳头状癌颈部淋巴结转移的处理态度和诊疗现状[J].实用肿瘤学杂志,2020,34(6):530-534.
[4] Huang Z,Sang T,Zheng Y,et al. Long non-coding RNA PANDAR overexpression serves as a poor prognostic biomarker in oral squamous cell carcinoma [J]. Int J Clin Exp Pathol,2018,11(5):2728-2734.
[5] 梁晗.血浆长链非编码RNA(LncRNA)ZFPM2-AS1和XIST在胃癌分子诊断中的研究[D].沈阳:中国医科大学,2020.
[6] 张超,李拓键.LncPANDAR通过靶向miR-637调控甲状腺癌增殖、转移的机制研究[J].重庆医科大学学报,2020,45(11):1557-1562.
[7] 李泽炎,肖志波.miRNA在黑色素瘤中的相关研究进展[J].中国美容整形外科杂志,2020,31(12):767-770.
[8] Liu J,Xu YW,Wu TT,et al. Tumor suppressor miR-637 is associated with cellular migration,invasion,and glioma diagnosis [J]. Int J Clin Med,2020,11(9):516-525.
[9] Du YM,Wang YB. MiR-637 inhibits proliferation and invasion of hepatoma cells by targeted degradation of AKT1 [J]. Eur Rev Med Pharmacol Sci,2019,23(2):567-575.
[10] 刘旭初,覃世运,陈丽君,等.食管鳞癌组织中LncRNA SNHG7的表达水平及与患者预后的关系[J].现代肿瘤医学,2020,28(13):2259-2263.
[11] Quinn JJ,Chang HY. Unique features of long non-coding RNA biogenesis and function [J]. Nat Rev Genet,2016, 17(1):47-62.
[12] 谷建斌,张国欣,张玉斌,等.胃癌组织中LncRNA SNHG3的表达及意义[J].河北医药,2020,42(23):3534-3537, 3542.
[13] 梁静,梁超,邢鲁奇.长链非编码RNA PCBP1-AS1在乳腺癌组织中的表达及临床意义[J].现代肿瘤医学,2020,28(13):2242-2245.
[14] Sang Y,Tang J,Li S,et al. LncRNA PANDAR regulates the G1/S transition of breast cancer cells by suppressing p16(INK4A) expression [J]. Sci Rep,2016,6(2):22366.
[15] Zhan Y,Lin J,Liu Y,et al. Up-regulation of long non-coding RNA PANDAR is associated with poor prognosis and promotes tumorigenesis in bladder cancer [J]. J Exp Clin Cancer Res,2016,35(1):83.
[16] Xu Y,Jiang X,Cui Y. Upregulated long noncoding RNA PANDAR predicts an unfavorable prognosis and promotes tumorigenesis in cholangiocarcinoma [J]. Onco Targets Ther,2017,10(1):2873-2883.
[17] Li X,Zhang L,Song P,et al. Long non-coding RNA PANDAR promotes melanoma cell invasion through regulating epithelial-mesenchymal transition [J]. Int J Clin Exp Pathol,2018,11(5):2430-2439.
[18] 方松城,修霞,麦潋曦,等.长非编码RNA PANDAR在舌鳞状细胞癌中的功能研究[J].岭南现代临床外科,2019, 19(6):701-705.
[19] 黄永塔,莫祥兰.miRNA与肿瘤转移调控机制的研究进展[J].中国临床新医学,2020,13(1):94-98.
[20] Lu TX,Rothenberg ME. MicroRNA[J]. J Allergy Clin Immunol,2018,141(4):1202-1207.
[21] Liao H,Pan Y,Pan Y,et al. MicroRNA 874 is downregulated in cervical cancer and inhibits cancer progression by directly targeting ETS1 [J]. Oncol Rep,2018,40(4):2389-2398.
[22] 李家新.MiR-637通过靶向调控CTSB抑制胆管癌QBC939细胞增殖与活力[D].南京:南京医科大学,2018.
[23] Wang Y,Wang X,Zhang J,et al. MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas [J]. J Neurooncol,2012,106(2):217-224.
[24] 刘玉海,刘明明,刘新华.miR-637调控CDK6/cyclinD1/Rb信号通路对人胃癌细胞增殖、迁移和侵袭的影响[J].安徽医科大学学报,2019,54(11):1672-1677.
[25] 袁青领.MicroRNA-637靶向调控AKT3对甲状腺乳头状癌细胞侵袭转移的影响及机制研究[D].郑州:郑州大学,2018. |
|
|
|